BeOne Medicines (ONC) Income from Continuing Operations (2015 - 2026)
BeOne Medicines (ONC) posted quarterly Income from Continuing Operations of 227357000.0 for Q1 2026, up 17802.13% year-over-year from N/an in Q1 2025, and up 241.88% quarter-over-quarter from 66502000.0 in Q4 2025.
BeOne Medicines (ONC) Income from Continuing Operations (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Income from Continuing Operations for 12 consecutive years, with 227357000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 17802.13% year-over-year to 227357000.0; the TTM figure through Mar 2026 stood at 513020000.0 (up 230.75% YoY), while the FY2025 annual figure was 286933000.0, up 144.5% from the prior year.
- Income from Continuing Operations climbed to 227357000.0 in Q1 2026 per ONC's latest filing, from 66502000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 227357000.0 in Q1 2026 and bottomed at 565726000.0 in Q2 2022.
- Historically, Income from Continuing Operations has averaged 177412882.35 across 5 years, with a median of 151881000.0 in 2024.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations plunged 754.48% — and 2026, when it surged 17802.13%.
- BeOne Medicines' Income from Continuing Operations stood at 445335000.0 in 2022, then climbed by 17.47% to 367553000.0 in 2023, then surged by 58.68% to 151881000.0 in 2024, then surged by 143.79% to 66502000.0 in 2025, then soared by 241.88% to 227357000.0 in 2026.
- Business Quant data shows ONC's Income from Continuing Operations at 227357000.0 in Q1 2026, 66502000.0 in Q4 2025, and 124841000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -290.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 237.01 Mn |
| Mar 31, 2026 | 227.36 Mn |
| Dec 31, 2025 | 66.50 Mn |
| Sep 30, 2025 | 124.84 Mn |
| Jun 30, 2025 | 94.32 Mn |
| Mar 31, 2025 | 1.27 Mn |
| Dec 31, 2024 | -151.88 Mn |
| Sep 30, 2024 | -121.35 Mn |
| Jun 30, 2024 | -120.41 Mn |
| Mar 31, 2024 | -251.15 Mn |
| Dec 31, 2023 | -367.55 Mn |
| Sep 30, 2023 | 215.41 Mn |
| Jun 30, 2023 | -381.14 Mn |
| Mar 31, 2023 | -348.43 Mn |
| Dec 31, 2022 | -445.34 Mn |
| Sep 30, 2022 | -557.56 Mn |
| Jun 30, 2022 | -565.73 Mn |
| Mar 31, 2022 | -435.20 Mn |
| Dec 31, 2021 | -590.68 Mn |
| Sep 30, 2021 | -438.11 Mn |